High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology
- 16 July 2013
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 40 (11) , 1701-1710
Abstract
Purpose Scintigraphy using 123I-metaiodobenzylguanidine (123I-MIBG) is widely used for the detection of neuroblastic tumours. The aim of this study was to identify a possible correlation between the uptake intensity on 123I-MIBG SPECT and histopathology of neuroblastic tumours. Methods 123I-MIBG SPECT examinations were performed in 55 paediatric patients with neuroblastic tumour and compared to histopathology after surgical resection or biopsy at a mean of 2 weeks after SPECT. For each lesion International Neuroblastoma Pathology Classification System (INPC) stage, mitosis karyorrhexis index (MKI), location and a semiquantitative tumour-to-liver count-rate ratio (TLCRR) were determined. Also, the presence or absence of MYCN amplification, p1 deletion, urine catecholamine and neuron-specific enolase blood levels at the time of scanning were recorded. Results In the 55 patients, 61 lesions were evaluated with 123I-MIBG SPECT and corresponding histopathological findings were reviewed (11 ganglioneuroma, 11 ganglioneuroblastoma and 39 neuroblastoma). TLCRR was significantly higher in the neuroblastoma group (mean TLCRR 2.7) than in the ganglioneuroblastoma group (mean TLCRR 1.0) and ganglioneuroma group (mean TLCRR 0.7) at the time of primary diagnosis (p < 0.001) and at follow-up (p = 0.039). Intense 123I-MIBG uptake was found in tumour tissue with a high mitotic activity (MKI-high or MKI-intermediate) after treatment. Four ganglioneuromas (36 %), three ganglioneuroblastomas (27 %) and six neuroblastomas (15 %) were 123I-MIBG-negative. Conclusion In paediatric patients with peripheral neuroblastic tumours, strong 123I-MIBG uptake indicates unfavourable histopathology. High uptake was seen in neuroblastomas and in tumours with a high mitotic activity.Keywords
This publication has 30 references indexed in Scilit:
- Tumor histology during induction therapy in patients with high‐risk neuroblastomaPediatric Blood & Cancer, 2011
- Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of AgeJournal of Clinical Oncology, 2011
- Pediatrics: Diagnosis of NeuroblastomaSeminars in Nuclear Medicine, 2011
- Diagnostic and prognostic information obtained on fine‐needle aspirates of primary neuroblastic tumorsCancer Cytopathology, 2011
- 123I-MIBG Scintigraphy and 18F-FDG PET in NeuroblastomaJournal of Nuclear Medicine, 2009
- 123I‐mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trialPediatric Blood & Cancer, 2009
- Chromosome 1p and 11q Deletions and Outcome in NeuroblastomaNew England Journal of Medicine, 2005
- The international neuroblastoma risk groups (INRG): a preliminary reportEuropean Journal of Cancer, 1997
- Adrenal cortical and medullary imagingSeminars in Nuclear Medicine, 1995
- Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow‐up treatment with a review of the diagnostic results of the international workshop of pediatric oncology held in Rome, september 1986Medical and Pediatric Oncology, 1987